louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06725303: Excimer Light Versus Blue Light in Acne
Official title: Excimer Light Versus Blue Light in the Treatment of Inflammatory Acne, a Split Face Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acne Vulgaris
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-10
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim is to assess the efficacy and safety of Excimer Light versus blue light in the treatment of inflammatory acne.

Detailed description: The use of new light energy in inflammatory acne

Eligibility criteria: Inclusion Criteria:

* Patients with mild to moderate inflammatory acne lesions

Exclusion Criteria:

* Pregnancy during the first trimester

  * Female patients with a medical history of PCO
  * Topical and systemic treatment within the last month and systemic retinoids for 6 months
  * Patients on systemic steroid treatment or hormonal therapy
  * Severe systemic illness or malignancy
  * Photosensitivity
  * Scarring acne vulgaris

Primary outcomes:
measure: Number of comedones, papules and pustules
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01895803: The Factors That Inhibit Women Who Smoke to do Pap Smear Test
Official title: To Find Factors That Inhibit Women Who Smoke to do Pap Smear Test
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Smoking Woman
18-60 Years Old
Keywords: smoking woman
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2013-07-11
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: smoking woman 18-60 years old

Brief summary: Discovery of factors affect the decision of the woman to perform or not to perform a Pap test.Participate in the study 100 women who smoke. Age range 18-60

Detailed description: The data collected through questionnaires to the women. Data analysis will be performed by using Statistical Analysis- SPSS

Eligibility criteria: Inclusion Criteria:

* smoking woman 18-60 years old

Exclusion Criteria:

* not smoking Not want to participate in the study

Primary outcomes:
measure: Why does not a woman who smokes do Pap test
timeFrame: 2 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Afllalo Yael
Study officials:
References:
Clinical trial NCT01594203: Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Soft Tissue Sarcoma (STS)
Keywords: Soft Tissue Sarcoma
Pazopanib
F18-FDG PET/CT
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2012-05-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with advanced Soft Tissue Sarcoma prior to pazopanib therapy

Brief summary: Soft Tissue Sarcoma (STS) is a rare tumor but can grow in different areas, for example, in 60% in limbs and about 20 % in retroperitoneum; and frequently is inoperable. Despite novel therapy in advanced cases survival is still short, approximately 12 month.

Pazopanib oral angiogenesis inhibitor was recently shown as promising drug for advanced pretreated STS.

Functional imaging especially F18-FDG PET/CT is a good modality for FDG avid tumor either for pre- / post- treatment evaluation or follow up.

Early detection of treatment response to therapy by whole body FDG PET/CT allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources.

The aim of the study is to investigate the contribution of FDG PET/CT to assessment of treatment response.


Eligibility criteria: Inclusion Criteria:

* Patients with advanced Soft Tissue Sarcoma prior to pazopanib treatment

Exclusion Criteria:

* Other treatment
* FDG negative tumor

Primary outcomes:
measure: Measure of extent and intensity (standardized uptake value - SUV) of disease demonstrated on PET/CT images before and after treatment.
timeFrame: 1 week
measure: determination of treatment efficiency by comparison of PET data (SUV) with CT changes (cm)in 3 studies and clinical information.
timeFrame: 4 week
Secondary outcomes:
measure: prediction of treatment efficiency
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Hebrew University Medical Center
Study officials:
References:
Clinical trial NCT06643403: Age-related Changes in Retinal Oxygen Extraction in Healthy Subjects
Official title: Age-related Changes in Retinal Oxygen Extraction in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: To Investigate Retinal Oxygen Extraction in Different Age Groups of Healthy Individuals
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2024-10-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: It has been found that several systemic and ocular diseases are associated with impaired retinal oxygen extraction. In the present study, retinal oxygen extraction will be measured in different age groups in order to identify age related changes in otherwise healthy subjects. In addition, the study will explore short-term changes in retinal metabolism induced by breathing pure oxygen. Measurements will be performed with dynamic vessel analyzer and laser speckle flowgraphy to evaluate retinal blood flow and retinal oxygen saturation, in order to calculate retinal oxygen extraction.


Eligibility criteria: Inclusion Criteria:

* Men and women aged between 18 and 80 years
* Signed informed consent
* Normal ophthalmic findings, unless the investigator considers an abnormality to be clinically irrelevant for the purpose of the study
* Normal findings in the medical history, unless the investigator considers an abnormality to be clinically irrelevant for the purpose of the study
* Nonsmokers

Exclusion Criteria:

* Abuse of alcoholic beverages or drugs
* Participation in a clinical trial in the 3 weeks preceding the study
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Blood donation during the previous 3 weeks
* Pregnant or breast-feeding women

Primary outcomes:
measure: Retinal oxygen extraction in different age groups
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Clinical Pharmacology, Medical University of Vienna, Austria
Study officials:
References:
Clinical trial NCT00599703: Language Function in Patients With Brain Tumors
Official title: Reorganization of Language Function in Patients With Brain Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Cancer
CNS Cancer
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2008-01-24
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MSKCC clinics

Brief summary: The purpose of this study is to use an imaging method called functional magnetic resonance imaging (fMRI) in patients who have a tumor near an area of the brain that is believed to control language. The fMRI is a new kind of imaging that uses a strong magnetic field to look at functioning brain tissue. This kind of imaging will be used to study the effect of the brain tumor on your speech.


Eligibility criteria: Inclusion Criteria:

* Patient in whom a tumor invades or is directly adjacent to the expected location of one of the language centers.
* At least 18 years of age
* English as first language

Exclusion Criteria:

* Patients with high grade tumors
* History of significant psychiatric condition (e.g. schizophrenia, obsessive-compulsive disorder, significant dementia),
* History of the following neurological conditions: CVA, demyelinating conditions, cerebral palsy, Alzheimer's disease.
* History of significant claustrophobic reactions.
* Pregnancy
* Standard contraindications to MR examinations (e.g. implanted stimulator)
* Patients, who were treated prior to our first scan, will not be eligible to participate in this study

Primary outcomes:
measure: To identify language organization prior to surgery in patients in whom a tumor invades or is directly adjacent to the expected location of one of the language centers.
timeFrame: conclusion of study
Secondary outcomes:
measure: To assess language reorganization over time.
timeFrame: conclusion of study
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Andrei Holodny, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04697303: Cross-sectional Study of Anorectal Function and Quality of Life in Patients With Middle and Low Rectal Cancer
Official title: Cross-sectional Study of Anorectal Function and Quality of Life in Patients With Middle and Low Rectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rectal Cancer
Lead sponsor: The First Hospital of Jilin University
Sponsor class: OTHER
First posted: 2021-01-06
Enrollment: 600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Postoperative patients with middle and low rectal cancer

Brief summary: Understanding the quality of life and anorectal function changes in patients with middle and low rectal cancer after surgery can guide patients to recover after surgery and provide a valuable reference for surgeons in the selection of surgical methods. The purpose of this study is to: (1) Investigate the complication rate, recurrence and metastasis rate and survival of patients with middle and low rectal cancer. (2) QLQ-C30 and QLQ-CR29 questionnaires were used to assess the quality of life of patients with low- and middle-level rectal cancer at different periods after surgery. (3) Wexner constipation score and LARS syndrome score for anorectal function after operation for low rectal cancer. (4) The CIPE ejaculatory function score, IIEF-5 International Erectile Function Score, and FSFI-6 Female Sexual Function Index were used to assess the changes in sexual function of patients with low- and middle-position rectal cancer after surgery.


Eligibility criteria: Inclusion Criteria:

1. Postoperative patients with middle rectal cancer
2. Postoperative patients with low rectal cancer

Exclusion Criteria:

(1)Patients refused to participate

Primary outcomes:
measure: Overall survival
timeFrame: five years after the operation
Secondary outcomes:
measure: QLQ-C30
timeFrame: Every three months after the operation
measure: QLQ-CR29
timeFrame: Every three months after the operation
measure: Wexner
timeFrame: Every three months after the operation
measure: LARS
timeFrame: Every three months after the operation
measure: IIEF-5
timeFrame: Every three months after the operation
measure: CIPE
timeFrame: Every three months after the operation
measure: FSFI-6
timeFrame: Every three months after the operation
Other outcomes:
Locations:
city: Changchun
country: China
facility: Jilin University First Hospital
state: Jilin
Study officials:
References:
Clinical trial NCT06116903: Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Official title: Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Glioma
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2023-11-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Detailed description: Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and their management complex. The molecular profiling from circulating exosomes is one of the most promising approaches to better characterize gliomas.

We will demonstrate the superiority of detection by NGS of molecular abnormalities present in exosomes from glioblastomas, compared to detection by the Foundation One Liquid CDx test on ctDNA.

Eligibility criteria: Inclusion Criteria:

* Subject of both sexes at least 18 years of age with glioblastoma.
* Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
* Patient affiliated to French social security

Exclusion Criteria:

* Patient included in another research protocol using an experimental molecule.
* Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
* Patient under legal protection, guardianship or curatorship
* Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

Primary outcomes:
measure: Analyse Next-generation sequencing (NGS)
timeFrame: 3 months
Secondary outcomes:
measure: Expression of biomarkers
timeFrame: 3 months
measure: Molecular alterations
timeFrame: 3 months
measure: carbon footprint
timeFrame: 3 months
Other outcomes:
Locations:
city: Limoges
country: France
facility: CHU de Limoges
Study officials:
References:
Clinical trial NCT01800903: Safety and Performance of a New Coating for Urinary Intermittent Catheters
Official title: Clinical Study Investigating Safety and Performance of a New Coating for Urinary Intermittent Catheters in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intermittent Urethral Catheterization
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2013-02-28
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate safety and performance of a new catheter coating,compared to the current SpeediCath coating.


Eligibility criteria: Inclusion Criteria:

1. Have given written informed consent and signed letter of authority
2. Be at least 18 years of age and have full legal capacity
3. Be a male
4. Willing to refrain from using analgetics up to 24 hours prior to catheterization visits

Exclusion Criteria:

1. Abnormalities, diseases or surgical procedures performed in the lower urinary tract
2. Symptoms of urinary tract infections (at least one of the following: frequent urination, stinging or pain at urination)
3. Participating in other interventional clinical investigations during this investigation (inclusion to termination) or have previously participated in this investigation (including run-in period)
4. Known hypersensitivity toward any of the test products -

Primary outcomes:
measure: Overall Discomfort During Catheterization
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Urology
Study officials:
affiliation: Department of Urology, Rigshospitalet Denmark
name: Per Bagi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00465803: A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
Official title: Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open-angle Glaucoma
Ocular Hypertension
Keywords: Open-angle glaucoma or ocular hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2007-04-25
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria: Inclusion Criteria:

* Adult patients with open-angle glaucoma or ocular hypertension;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Visual acuity worse than 0.60;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Patient compliance
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Seattle
state: Washington
Study officials:
affiliation: Alcon Research
name: Theresa Landry
role: STUDY_DIRECTOR
References:
Clinical trial NCT02396303: Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Postpartum Haemorrhage
Keywords: General: To compare Carbetocin and Oxytocin for the control of PPH.
Lead sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Sponsor class: OTHER
First posted: 2015-03-24
Enrollment: 100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Post-partum haemorrhage is one of the life threatening emergencies. It accounts for nearly one-quarter of all maternal death worldwide. Atonic uterus contributes about 80% among the causes. Uterotonic drugs are administered following the delivery of baby both in vaginal and caesarean delivery for prevention of PPH. However postpartum haemorrhage cannot always be prevented. But, the incidence and especially its magnitude can be reduced by assessing the risk factors and following the guidelines. The intelligent anticipation, skilled supervision, prompt detection and effective institution of therapy can prevent a normal case from undergoing disastrous consequences. This study will be carried out at Bangabandhu Sheikh Mujib Medical University (BSMMU) within six months after approval. This is a Randomized Control Trial which will compare efficacy of Carbetocin and Oxytocin for the control of PPH. Structured Questionnaire, Data Sheet, hospital indoor documents i.e. Patient chart, operation notes, surgeons visual estimation of blood loss etc will be used as study tool. Ethical clearance will be obtained from Institutional Review Board of BSMMU. Written informed consent will be obtained from the patient or from her legal guardian. Patient confidentiality will be strictly maintained. No name, address or contact details of the patient will be divulged.


Eligibility criteria: Inclusion Criteria:

* Patient with risk factors for primary post-partum haemorrhage such as: multiple pregnancy, one or more previous caesarean section, presence of uterine fibroids, previous myomectomy, presence of placenta previa, past history of PPH, fetal macrosomia and fetal malformations associated with polyhydramnios

Exclusion Criteria:

* Presence of hypertension, eclampsia, cardiac, renal or liver diseases, epilepsy, general anaesthesia, as well as women with history of hypersensitivity to Carbetocin according to the Br National Formulary. Patients unwilling to give consent for this study are also excluded

Primary outcomes:
measure: Estimated blood loss after cesarean section
timeFrame: 24 hours of delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: BSMMU
Study officials:
References:
Clinical trial NCT02577003: Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Official title: A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2015-10-15
Enrollment: 143
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy. The primary hypothesis for this study is that the addition of ipragliflozin compared with placebo provides greater reduction in hemoglobin A1C (HbA1c) as assessed by change from baseline at Week 24.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes mellitus
* Inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy
* HbA1c ≥7.0% and ≤10.0% before study start

Exclusion Criteria:

* History of Type 1 diabetes mellitus or a history of ketoacidosis
* History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation and sodium glucose cotransporter 2 (SGLT2) inhibitors anytime
* Currently has a urinary tract infection or genital infection with subjective symptom

Primary outcomes:
measure: Change From Baseline in HbA1c at Week 24
timeFrame: Baseline and Week 24
measure: Percentage of Participants Who Experienced at Least One Adverse Event (AE)
timeFrame: Up to 26 weeks
measure: Percentage of Participants Who Discontinued Study Drug Due to an AE
timeFrame: Up to 24 weeks
Secondary outcomes:
measure: Change From Baseline in FPG at Week 24
timeFrame: Baseline and Week 24
measure: Change From Baseline in 2-hr PMG at Week 24
timeFrame: Baseline and Week 24
measure: Change From Baseline in Glucose Total AUC0-2hr After Meal at Week 24
timeFrame: Baseline and Week 24 (just before the loading meal [0 min], 30 min, 60 min and 120 min)
measure: Change From Baseline in Body Weight at Week 24
timeFrame: Baseline and Week 24
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Kaku K, Kadowaki T, Seino Y, Okamoto T, Shirakawa M, Sato A, O'Neill EA, Engel SS, Kaufman KD. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes Obes Metab. 2021 Sep;23(9):2099-2108. doi: 10.1111/dom.14448. Epub 2021 Jun 15.